• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Rafael Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    10/29/25 4:36:55 PM ET
    $RFL
    Real Estate
    Finance
    Get the next $RFL alert in real time by email
    false 0001713863 0001713863 2025-10-29 2025-10-29 0001713863 RFL:ClassBCommonStockParValue0.01PerShareMember 2025-10-29 2025-10-29 0001713863 RFL:WarrantToPurchaseClassBCommonStockMember 2025-10-29 2025-10-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): October 29, 2025

     

     

     

    RAFAEL HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   1-38411   82-2296593

    (State or other jurisdiction

    of Incorporation)

      (Commission File Number)  

    (IRS Employer

    Identification No.)

     

    520 Broad Street

    Newark, New Jersey

      07102
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: 212 658-1450

     

    Not Applicable

    (Former name or former address, if changed since last report.)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company   ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

     

    Securities registered pursuant to Section 12(b)-2 of the Exchange Act:

     

    Title of each class   Trading Symbol  

    Name of each exchange on which registered

    Class B common stock, par value $0.01 per share   RFL   New York Stock Exchange
    Warrant to Purchase Class B common stock   RFL-WT   NYSE American

     

     

     

     

     

     

    Item 2.02. Results of Operations and Financial Condition.

     

    On October 29, 2025, Rafael Holdings, Inc. (the “Company”) distributed over a wire service and posted an earnings release to the investors page of its website (www.rafaelholdings.com) announcing its results of operations for the fiscal quarter and fiscal year ended July 31, 2025. A copy of the earnings release concerning the foregoing results is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

     

    The Company is furnishing the information contained in this Report, including Exhibit 99.1, pursuant to Item 2.02 of Form 8-K promulgated by the Securities and Exchange Commission (the “SEC”). This information shall not be deemed to be “filed” with the SEC or incorporated by reference into any other filing with the SEC unless otherwise expressly stated in such filing. In addition, this Report and the press release contain statements intended as “forward-looking statements” that are subject to the cautionary statements about forward-looking statements set forth in the press release.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Document
    99.1   Press Release, dated October 29, 2025, reporting the results of operations for the fiscal quarter and fiscal year ended July 31, 2025.
    104   Cover Page Interactive Data File, formatted in Inline XBRL document.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      RAFAEL HOLDINGS, INC.
           
      By: /s/ David Polinsky
        Name:  David Polinsky
        Title:  Chief Financial Officer

     

    Dated: October 29, 2025

     

    2

     

     

    EXHIBIT INDEX

     

    Exhibit
    Number
      Document
    99.1   Press Release, dated October 29, 2025, reporting the results of operations for the fiscal quarter and fiscal year ended July 31, 2025.
    104   Cover Page Interactive Data File, formatted in Inline XBRL document.

     

    3

     

    Get the next $RFL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RFL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RFL
    SEC Filings

    View All

    SEC Form 10-K filed by Rafael Holdings Inc.

    10-K - Rafael Holdings, Inc. (0001713863) (Filer)

    10/29/25 5:19:30 PM ET
    $RFL
    Real Estate
    Finance

    Rafael Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Rafael Holdings, Inc. (0001713863) (Filer)

    10/29/25 4:36:55 PM ET
    $RFL
    Real Estate
    Finance

    Rafael Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Rafael Holdings, Inc. (0001713863) (Filer)

    10/28/25 4:11:34 PM ET
    $RFL
    Real Estate
    Finance

    $RFL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Grayson Alan claimed no ownership of stock in the company (SEC Form 3)

    3 - Rafael Holdings, Inc. (0001713863) (Issuer)

    10/31/25 3:07:03 PM ET
    $RFL
    Real Estate
    Finance

    Chief Financial Officer Polinsky David covered exercise/tax liability with 4,180 units of Class B Common Stock, decreasing direct ownership by 2% to 260,641 units (SEC Form 4)

    4 - Rafael Holdings, Inc. (0001713863) (Issuer)

    10/28/25 3:12:55 PM ET
    $RFL
    Real Estate
    Finance

    Chief Financial Officer Polinsky David covered exercise/tax liability with 1,284 units of Class B Common Stock, decreasing direct ownership by 0.48% to 264,821 units (SEC Form 4)

    4 - Rafael Holdings, Inc. (0001713863) (Issuer)

    9/25/25 2:34:43 PM ET
    $RFL
    Real Estate
    Finance

    $RFL
    Leadership Updates

    Live Leadership Updates

    View All

    Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

    NEWARK, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) sadly announced today the passing of its Lead Independent Director, Stephen Greenberg, and the appointment of Alan Grayson to its Board of Directors. Mr. Grayson will serve on the Compensation, Corporate Governance and Nominating Committees. Separately, the Company also announced that Markus Sieger, an existing Board member, will join the Audit Committee as its Chair and has been elected as Lead Independent Director. Stephen Greenberg had served on Rafael's Board since March 2018 bringing with him a wealth of experience, insights, and guidance. Mr. Greenberg had served as a director of Zedge, Inc. f

    10/28/25 4:01:00 PM ET
    $RFL
    Real Estate
    Finance

    Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

    Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common

    8/22/24 6:50:00 AM ET
    $CYTH
    $RFL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Real Estate
    Finance

    Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

    Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common stock to Cyclo Therapeutics' shareholders, based on an exchange ratio

    8/22/24 6:50:00 AM ET
    $CYTH
    $RFL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Real Estate
    Finance

    $RFL
    Financials

    Live finance-specific insights

    View All

    Rafael Holdings Provides Update on Rafael Pharmaceuticals' Two Phase 3 Trials of CPI-613® (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute Myeloid Leukemia

    Phase 3 Clinical Trial in Metastatic Pancreatic Cancer Did Not Meet its Primary Endpoint of Improved Overall Survival Independent Data Monitoring Committee Recommended the Phase 3 Clinical Trial in Relapsed or Refractory Acute Myeloid Leukemia Be Stopped Due to Lack of Efficacy Rafael Holdings to Host Conference Call Today at 8:00 a.m. ET NEWARK, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE:RFL), a holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute, investment in Rafael Pharmaceuticals, Inc. ("Rafael Pharmaceuticals") as well as other investments in early-stage ventures, today announced that the AVENGER 500 Phas

    10/28/21 7:00:00 AM ET
    $RFL
    Real Estate
    Finance

    $RFL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Rafael Holdings Inc.

    SC 13D/A - Rafael Holdings, Inc. (0001713863) (Subject)

    9/30/24 5:40:03 PM ET
    $RFL
    Real Estate
    Finance

    Amendment: SEC Form SC 13D/A filed by Rafael Holdings Inc.

    SC 13D/A - Rafael Holdings, Inc. (0001713863) (Subject)

    6/18/24 6:12:11 PM ET
    $RFL
    Real Estate
    Finance

    SEC Form SC 13D/A filed by Rafael Holdings Inc. (Amendment)

    SC 13D/A - Rafael Holdings, Inc. (0001713863) (Filed by)

    10/24/23 4:43:18 PM ET
    $RFL
    Real Estate
    Finance

    $RFL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Exec Chairman, CEO & President Jonas Howard S bought $16,742,985 worth of Class B Common Stock (13,080,457 units at $1.28) (SEC Form 4)

    4 - Rafael Holdings, Inc. (0001713863) (Issuer)

    6/9/25 5:19:19 PM ET
    $RFL
    Real Estate
    Finance

    $RFL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

    Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is continuing at the recommendation of the Data Monitoring Committee (DMC) following their review of prespecified safety and efficacy date at 48 weeks On August 4, 2025, Joshua Fine was elected as the Company's Chief Operating Officer NEWARK, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL), today reported its financial results for the fourth quarter and full fiscal year 2025 ended July 31, 2025. "We are pleased with the continued progress of our pivotal Phase 3 TransportNPC™ study evaluatin

    10/29/25 4:24:40 PM ET
    $RFL
    Real Estate
    Finance

    Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

    NEWARK, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) sadly announced today the passing of its Lead Independent Director, Stephen Greenberg, and the appointment of Alan Grayson to its Board of Directors. Mr. Grayson will serve on the Compensation, Corporate Governance and Nominating Committees. Separately, the Company also announced that Markus Sieger, an existing Board member, will join the Audit Committee as its Chair and has been elected as Lead Independent Director. Stephen Greenberg had served on Rafael's Board since March 2018 bringing with him a wealth of experience, insights, and guidance. Mr. Greenberg had served as a director of Zedge, Inc. f

    10/28/25 4:01:00 PM ET
    $RFL
    Real Estate
    Finance

    Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

    First data on treatment of NPC1 with Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin) in this age group over a period of 48 weeks At 48 weeks of the sub-study, 7 of 9 patients1 showed stabilization or improvement in CGI-S score Data presented at the15th International Congress of Inborn Errors of Metabolism (ICIEM) NEWARK, N.J., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) announced today that data from Cyclo Therapeutics' Phase 3 TransportNPC™ open-label, single-arm sub-study evaluating Trappsol® Cyclo™ (hydroxypropyl-beta-cyclodextrin) for Niemann-Pick Disease Type C1 ("NPC1") were presented at the 15th International Congress of Inborn Errors of Metab

    9/16/25 8:00:00 AM ET
    $RFL
    Real Estate
    Finance